Valuation as at 2026-08-14 · see also the Europe Most Undervalued screen
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Sanofi SAN.PA
Healthcare · Drug Manufacturers - General
Sanofi's price & financial trends
Each card is labelled with its own reporting period — quarterly where Yahoo provides it for this market, annual otherwise.
Data as at 2026-08-14
Share price · last 2 years
Earnings per share (diluted) Per quarter
Free cash flow Per quarter
Dividend per share Per year
Value investing scale · Buffett · Dalio · Graham
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | -7.5% | -5.0% | -2.5% |
| Terminal growth | 1.8% | 1.8% | 1.8% |
| WACC (discount rate) | 6.32% | 5.32% | 4.32% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 3.20% + 0.50 × 5.50% = 5.95% · WACC = weighted by 80%/20% capital structure
These numbers come from running Sanofi's cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or SAN.PA's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with SAN.PA →
More stocks we've valued
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full DCF tool and the Europe Most Undervalued screen. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is Sanofi (SAN.PA) undervalued?
The Base-case DCF estimates intrinsic value at €112.38 vs a price of €76.43 on 2026-08-14 — a +47.0% margin, so the Base case reads undervalued. This is a mechanical output, not advice.